Boc-Lys-OHCAS# 13734-28-6 |
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
- Z-VAD-FMK
Catalog No.:BCC1126
CAS No.:187389-52-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- Apoptosis Activator 2
Catalog No.:BCC2099
CAS No.:79183-19-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 13734-28-6 | SDF | Download SDF |
| PubChem ID | 100148 | Appearance | Powder |
| Formula | C11H22N2O4 | M.Wt | 246.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 6-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid | ||
| SMILES | CC(C)(C)OC(=O)NC(CCCCN)C(=O)O | ||
| Standard InChIKey | DQUHYEDEGRNAFO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C11H22N2O4/c1-11(2,3)17-10(16)13-8(9(14)15)6-4-5-7-12/h8H,4-7,12H2,1-3H3,(H,13,16)(H,14,15) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Boc-Lys-OH Dilution Calculator
Boc-Lys-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.0601 mL | 20.3004 mL | 40.6009 mL | 81.2018 mL | 101.5022 mL |
| 5 mM | 0.812 mL | 4.0601 mL | 8.1202 mL | 16.2404 mL | 20.3004 mL |
| 10 mM | 0.406 mL | 2.03 mL | 4.0601 mL | 8.1202 mL | 10.1502 mL |
| 50 mM | 0.0812 mL | 0.406 mL | 0.812 mL | 1.624 mL | 2.03 mL |
| 100 mM | 0.0406 mL | 0.203 mL | 0.406 mL | 0.812 mL | 1.015 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Boc-Lys-OH
- Thrombin Receptor Agonist Peptide
Catalog No.:BCC3950
CAS No.:137339-65-2
- LY 215840
Catalog No.:BCC7101
CAS No.:137328-52-0
- Cathepsin S inhibitor
Catalog No.:BCC1455
CAS No.:1373215-15-6
- Dehydroeffusol
Catalog No.:BCN2927
CAS No.:137319-34-7
- 4,5-Dioxo-4,5-seco-11(13)-cadinen-12-oic acid
Catalog No.:BCN1577
CAS No.:137288-61-0
- 4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pymol[2,3-d]pyrimodin-5-yl)ethyl]benzoic acid
Catalog No.:BCC8670
CAS No.:137281-39-1
- Pemetrexed
Catalog No.:BCC9115
CAS No.:137281-23-3
- Boc-Gln-OH
Catalog No.:BCC3382
CAS No.:13726-85-7
- Boc-Glu(OtBu)-OH
Catalog No.:BCC3392
CAS No.:13726-84-6
- Boc-Hyp-OH
Catalog No.:BCC3251
CAS No.:13726-69-7
- Boc-Asp-OH
Catalog No.:BCC2609
CAS No.:13726-67-5
- Chlorantholide E
Catalog No.:BCN4836
CAS No.:1372558-36-5
- Boc-Phe-OH
Catalog No.:BCC3432
CAS No.:13734-34-4
- Boc-Sar-OH
Catalog No.:BCC3337
CAS No.:13734-36-6
- Boc-Ser(tBu)-OH
Catalog No.:BCC3444
CAS No.:13734-38-8
- Boc-Thr(tBu)-OH
Catalog No.:BCC3452
CAS No.:13734-40-2
- Boc-Val-OH
Catalog No.:BCC3465
CAS No.:13734-41-3
- GSK J1
Catalog No.:BCC2231
CAS No.:1373422-53-7
- GSK J4 HCl
Catalog No.:BCC2230
CAS No.:1373423-53-0
- Nω-Propyl-L-arginine hydrochloride
Catalog No.:BCC6965
CAS No.:137361-05-8
- PF-5274857
Catalog No.:BCC3838
CAS No.:1373615-35-0
- Spathulatol
Catalog No.:BCN6877
CAS No.:1373888-27-7
- Diacerein
Catalog No.:BCN2291
CAS No.:13739-02-1
- 15,16-Epoxy-15-ethoxy-6beta,13-dihydroxylabd-8-en-7-one
Catalog No.:BCN7428
CAS No.:1374328-47-8
Synthesis and biological activity of homoarginine-containing opioid peptides.[Pubmed:16967435]
J Pept Sci. 2007 Jan;13(1):27-30.
Two tris-alkoxycarbonyl homoarginine derivatives, Boc-Har{omega,omega'-[Z(2Br)]2}-OH and Boc-Har{omega,omega'-[Z(2Cl)]2}-OH, were prepared by guanidinylation of Boc-Lys-OH, and used for the synthesis of neo-endorphins and dynorphins. The results were compared with that obtained in the synthesis in which Boc-Lys(Fmoc)-OH was incorporated into the peptide chain, and after removing Fmoc protection, the resulting peptide-resin was guanidinylated with N,N'-[Z(2Br)]2- or N,N'-[Z(2Cl)]2-S-methylisourea. The peptides were tested in the guinea-pig ileum (GPI) and mouse vas deferens (MVD) assays. The results indicated that replacement of Arg by Har may be a good avenue for the design of biologically active peptides with increased resistance to degradation by trypsin-like enzymes.
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.[Pubmed:17628030]
Arch Pharm (Weinheim). 2007 Aug;340(8):389-95.
Cathepsin B and plasmin are intra- or extracellular proteases that are overexpressed by several solid tumors. In order to exploit both proteases as molecular targets for tumor-specific cleavage of prodrugs, an albumin-binding formulation of methotrexate was developed that incorporated the peptide sequence D-Ala-Phe-Lys as the protease substrate. Albumin is a suitable carrier for cytostatic agents due to passive accumulation in solid tumors. Synthesis was performed by coupling the peptide linker EMC-D-Ala-Phe-Lys(Boc)-Lys-OH (EMC = epsilon-maleimidocaproic acid) to the gamma-COOH group of alpha-tert-butyl protected methotrexate. After cleavage of the protective groups and purification on reverse phase HPLC, a highly water-soluble methotrexate-peptide derivative was obtained that binds rapidly and selectively to human serum albumin. The albumin-bound form of the prodrug was shown to be efficiently cleaved by cathepsin B and plasmin as well as in an ovarian carcinoma homogenate (OVCAR-3) liberating a methotrexate-lysine derivative. In an OVCAR-3 xenograft model, the prodrug at a dose of 4x15 mg/kg methotrexate equivalents demonstrated distinctly superior antitumor efficacy compared to free methotrexate at a dose of 4x100 mg/kg [T/C(%) for MTX = 69; T/C(%) for MTX prodrug = 29]. The data provide a further proof of concept for the development of albumin-binding, enzymatically cleavable prodrugs of anticancer drugs.
